None listed
Conditions
Brief summary
Increasing evidence suggested that oxidative stress exists in schizophrenia. Oxidative stress also has been indicate to contribute to metabolic syndrome and related disorders, including diabetes and cardiovascular disease, which are higher prevalence in schizophrenia compared to general population. Alpha-lipoic acid is a naturally occurring compound that is synthesized in small amounts by humans. It is found in spinach, potatoes, broccoli, red meats and liver. Orally supply alpha-lipoic acid has potent antioxidant activity. Beside, quenching free radicals, there is evidence that alpha-lipoic acid lead to regeneration endogenous antioxidants such as vitamins C and E, and GSH. Alpha-lipoic acid has been reported to has beneficial effect in many disease associated with increased oxidative stress, which could be a consequence of either increased production of free radicals or reduced antioxidant defenses.We hypothesized that LA would effects on increased oxidative stress in schizophrenia, as well as improved some metabolic risk factors, that are resulting in side effects of antipsychotic use.
Interventions
This study will evaluate the effect of alpha lipoic acid (LA) in patients with schizophrenia treated with antipsychotics drugs. In this open label, interventional study we will investigate LA effects (capsule with 500 mg LA, once day 30 min before meals for 90 days) on oxidative stress markers and antioxidative defence in patients with schizophrenia and compared to healthy controls. We hypothesize that LA will effects on increased oxidative stress in schizophrenia, as well as improve some metab
This study will evaluate the effect of alpha lipoic acid (LA) in patients with schizophrenia treated with antipsychotics drugs. In this open label, interventional study we will investigate LA effects (capsule with 500 mg LA, once day 30 min before meals for 90 days) on oxidative stress markers and antioxidative defence in patients with schizophrenia and compared to healthy controls. We hypothesize that LA will effects on increased oxidative stress in schizophrenia, as well as improve some metabolic risk factors, that are resulting in side effects of antipsychotic use. Compliance measured through the number of returned capsules.
Sponsors
University of Belgrade, Faculty of Pharmacy
Study design
Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
A ICD 10 diagnosis of schizophrenia Ability to give assent All patients on stable dose of antipsychotic drugs Otherwise medically stable Inclusion criteria for healthy controls were absence of any psychiatric and somatic disease.
Exclusion criteria
History of substance abuse or dependence Several medical disorders: severe head injury, seizure disorders diabetes, cancer, renal or liver diseases, pregnancy Oral contraceptives, hormone replacement therapy, hypolipidemic drugs, any food supplements at least 30 days before and during the study. Patients clinically unstable on current medication regimen
Outcome results
None listed